Results 41 to 50 of about 1,772,527 (156)

Proteomic Profiling of Nodal T‐Follicular Helper Cell Lymphoma Reveals Distinct Biological Signatures and Improves Prognostic Stratification Beyond the IPI

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Nodal T‐follicular helper cell lymphoma (nTFHL), most commonly of angioimmunoblastic type, exhibits heterogeneous clinical outcomes that are not fully explained by current clinical and biological variables. While genetic alterations have been extensively investigated, its proteomic landscape remains largely unexplored.
David Beauvais   +9 more
wiley   +1 more source

Stable donor hematopoiesis reconstitution after post-transplantation relapse of acute myeloid leukemia in patient with inv(3)(q21q26), –7 and EVI1 oncogene overexpression treated by donor lymphocyte infusions and hypomethylating agents

open access: yesКлиническая онкогематология, 2014
We present the case of successful treatment of post-transplantation relapse of prognostically unfavorable AML with inv(3)(q21q26), –7 and EVI1 oncogene overexpression, when stable donor hematopoiesis reconstitution was achieved due to one high-dose ...
N. N. Mamaev   +8 more
doaj   +1 more source

Prognostic Impact of FLT3‐ITD Allelic Ratio in AML Patients Treated With High‐Dose Anthracycline and a FLT3 Inhibitor

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The prognostic value of FLT3 internal tandem duplication (FLT3‐ITD) in acute myeloid leukemia (AML) has traditionally been stratified according to the ITD/wild‐type allelic ratio (AR) and NPM1 co‐mutation status. We evaluated the prognostic impact of FLT3‐ITD AR in 459 newly diagnosed AML patients younger than 60 years enrolled in the ...
Mathieu Leclerc   +43 more
wiley   +1 more source

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach

open access: yes, 2023
Hypomethylating agents (HMA) such as azacitidine and decitabine are a mainstay in the current management of patients with myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML) as either single agents or in multidrug combinations ...
Zhuoer Xie   +4 more
core   +1 more source

Circulating monocyte partitioning and its alteration in hematological chronic neoplasms

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi   +4 more
wiley   +1 more source

Angioimmunoblastic T‐cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review

open access: yesClinical Case Reports, 2020
The genomic landscape of AITL is characterized by mutation of epigenetic modifiers. This gene expression pattern resembles myeloid diseases and shows a potential role for hypomethylating agents as possible therapy for AITL.
Isabel Iturrate   +7 more
doaj   +1 more source

CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents

open access: yes, 2020
The prognostic impact of immunophenotypic CD34+CD38−CD123+ leukemic stem cell (iLSC) frequency at diagnosis has been demonstrated in younger patients treated by intensive chemotherapy, however, this is less clear in older patients. Furthermore, the
Huguet, Françoise   +27 more
core   +1 more source

Clinical applications of CD34+ progenitor cell immunophenotyping in myelodysplastic neoplasms—The CytHem SMD French network experience

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a risk of progression to acute myeloid leukemia. As the disease originates in hematopoietic stem and progenitor cells (HSPCs), flow cytometry (FCM) has emerged as a key approach to interrogate the bone ...
Nicolas Chapuis   +5 more
wiley   +1 more source

Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy

open access: yesMolecular Oncology, 2022
Testicular germ cell tumors (TGCTs) are aggressive but sensitive to cisplatin‐based chemotherapy. Alternative therapies are needed for tumors refractory to cisplatin with hypomethylating agents providing one possibility.
Ratnakar Singh   +12 more
doaj   +1 more source

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

open access: yes, 2021
Despite the success of the combination of venetoclax with the hypomethylating agents (HMA) decitabine or azacitidine in inducing remission in older, previously untreated patients with acute myeloid leukemia (AML), resistance - primary or secondary ...
John, August J.   +2 more
core  

Home - About - Disclaimer - Privacy